Italian study shows no improvement from Roche's rheumatoid arthritis drug for COVID-19

Roche Holding AG's Actemra did not improve symptoms in patients with early-stage COVID-19 pneumonia, scientists conducting a study of the drug in Italy said on Wednesday, raising questions about the potential of the Swiss drugmakers' rheumatoid arthritis drug to treat the novel coronavirus.

from RSSMix.com Mix ID 8260657 https://ift.tt/2Cj8FdR